Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Jun 2012
Case ReportsHeadache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine.
Harlequin syndrome (HS) is a rare autonomic disorder characterised by unilateral diminished sweating and flushing of the face in response to heat or exercise. Some patients with HS complain of headache. ⋯ These data do not show any correlation between the phenotypic expression of migraine and HS suggesting the syndromes are pathogenetically independent.
-
J. Neurol. Neurosurg. Psychiatr. · Jun 2012
ReviewCentral nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition.
The concept of antibody mediated CNS disorders is relatively recent. The classical CNS paraneoplastic neurological syndromes are thought to be T cell mediated, and the onconeural antibodies merely biomarkers for the presence of the tumour. ⋯ The clinical spectrum of these diseases is not yet fully explored, there may be others yet to be discovered and some types of more common disorders (eg, epilepsy or psychosis) may prove to have an autoimmune basis. Here, the known conditions associated with neuronal surface antibodies are briefly reviewed, some general aspects of these syndromes are considered and guidelines that could help in the recognition of further disorders are suggested.
-
J. Neurol. Neurosurg. Psychiatr. · Jun 2012
Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients.
The 10 year outcomes and impact of motor and non-motor features on survival of a cohort of new onset Chinese Parkinson's disease (PD) patients were prospectively studied. ⋯ 10 years into PD, a significant proportion of patients developed dopa resistant motor and non-motor features. Older onset, PIGD type, PIPon and dementia had a negative impact on survival. Standardised mortality ratio was 1.1.
-
J. Neurol. Neurosurg. Psychiatr. · May 2012
Randomized Controlled TrialLithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.
To determine the safety and efficacy of lithium for the treatment of amyotrophic lateral sclerosis (ALS) in a randomised, placebo controlled, double blind, sequential trial. ⋯ This trial, designed to detect a modest effect of lithium, did not demonstrate any beneficial effect on either survival or functional decline in patients with ALS.